Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia treated with venetoclax: a multicenter retrospective analysis.

ABSTRACT: Venetoclax showed promising activity in a small phase II trial in relapsed/refractory Waldenström macroglobulinemia (WM). To report the clinical activity of venetoclax and prognostic factors associated with outcomes in a larger cohort, we retrospectively identified 76 patients with relapsed/refractory lymphoplasmacytic lymphoma (LPL)/WM treated with venetoclax monotherapy at nine US medical centers. The median age at venetoclax treatment initiation was 66 years. MYD88, CXCR4, and TP53 mutations were detected in 65 (94%), 23 (40%), and 10 (22%) patients, respectively. The median number of prior lines of treatment was 3, including covalent BTK inhibitor in 82% and alkylating agent in 71% of patients. The overall and major response rates to venetoclax were 70% and 63%, respectively. The media

SUBMITTER: Sawalha Y 

PROVIDER: S-EPMC12000436 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature